Transcriptomic Biomarker Analysis – Colorectal Cancer

Colorectal cancer is one of the most common cancers, requiring precise molecular stratification to optimize diagnosis, management, and therapeutic follow-up. Gene expression analysis helps identify key biomarkers useful for predicting treatment response and detecting molecular alterations.

Genes Analyzed in Colorectal Cancer

Our panel targets genes involved in tumor progression, treatment resistance, and microsatellite instability, including:

• KRAS & NRAS – Mutations affecting the effectiveness of anti-EGFR targeted therapies

• BRAF (V600E) – Mutation associated with unfavorable prognosis and specific therapies

• TP53 – Tumor suppressor altered in more than 50% of colorectal cancers

• MLH1, MSH2, MSH6, PMS2 – Markers of microsatellite instability (MSI) and Lynch syndrome

• CTNNB1 (β-catenin) – Key gene in Wnt signaling, involved in tumor progression

Applications & Benefits

• Patient Stratification for precision medicine

• Identification of eligible patients for targeted therapies and immunotherapies

• Monitoring treatment response and detection of resistance

• Microsatellite instability (MSI) analysis to identify hypermutated tumors

Technologies Used

We use advanced approaches for reliable and robust analysis:

• RT-qPCR and RNA-seq (NGS) for accurate quantification of expression levels

• Nanostring and transcriptomic arrays for multiplexed gene analysis

• Dedicated genetic panels for MSI-H and MSS tumors

Contact us at contact@genxmap.com for an analysis tailored to your clinical or digestive oncology research project!